Clinical Trial

Qishenyiqi for Ventricular Remodeling After Myocardial Infarction

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The effects of Qishenyiqi dripping pill on cardiac remodeling in patients with chronic stable heart failure have not been reported. This project aims to clarify the efficacy and safety of Qishenyiqi in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure after myocardial infarction were selected and randomly divided into two groups: the treatment group was treated with Qishenyiqi dripping pills; The control group was given placebo treatment. After 12 months of follow-up, the effects of Qishenyiqi on cardiac remodeling and function and cardiovascular adverse events were evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure.
Trial Details
NCT Number NCT06699407
Lead Sponsor Qilu Hospital of Shandong University
Conditions Chronic Stable Heart Failure
Enrollment 210 participants
Start Date 2024-11-20
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-21